Charles River Laboratories International, Inc.’s Stock Price Drops to $178.08, Marking a 6.34% Decrease: A Critical Performance Analysis

Charles River Laboratories International, Inc. (CRL)

178.08 USD -12.06 (-6.34%) Volume: 1.87M

Charles River Laboratories International, Inc.’s stock price stands at 178.08 USD, experiencing a 6.34% decrease this trading session with a trading volume of 1.87M, reflecting a Year-To-Date (YTD) percentage change of -3.16%.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories stock experienced a 6% decline today after the company provided a dim outlook for its 2025 financial performance, disappointing investors. Despite William Blair reiterating an “Outperform” rating, JPMorgan maintained a Neutral stance citing challenges ahead. The company’s presentation at the J.P. Morgan Healthcare Conference shed light on the anticipated revenue drop for 2025, leading to a gap down in shares. Analysts at TD Cowen expressed caution as the 2025 guidance indicated further declines. Citi also flagged revenue and margin headwinds for Charles River Labs. With stock hitting a 52-week low at $176.34, it’s evident that investors are closely monitoring the company’s strategic overview amidst ongoing challenges.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. is positioned for strong long-term growth, according to Smartkarma Smart Scores. With high scores in Growth and Momentum, the company is expected to continue expanding and performing well in the future. Despite lower scores in Dividend and Resilience, Charles River Laboratories‘ focus on research tools and support services for drug discovery and development is likely to drive its success in the industry.

Charles River Laboratories International, Inc. is a key player in providing research tools and support services for pharmaceutical and biotechnology companies, hospitals, and academic institutions. The company’s Smartkarma Smart Scores indicate a positive outlook, especially in terms of growth potential and momentum. While there may be some challenges in terms of resilience and dividend payouts, Charles River Laboratories‘ dedication to facilitating drug discovery and development positions it well for long-term success in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma